Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...
16h
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
The Citizens Life Sciences Conference 2026 March 11, 2026 10:45 AM EDTCompany ParticipantsHelen Torley - President, ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...
As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...
Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...
The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
The global healthcare landscape is witnessing a transformative shift in the management of rare genetic disorders. At the forefront of this evolution stands the Hemophilia Therapeutics Market. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results